Quarterly Financial Data (Details) (USD $) Share data in Millions, except Per Share data, unless otherwise specified	3 Months Ended																12 Months Ended
	Jun. 28, 2014		Mar. 29, 2014		Dec. 28, 2013		Sep. 28, 2013		Jun. 29, 2013		Mar. 30, 2013		Dec. 29, 2012		Sep. 29, 2012		Jun. 28, 2014	Jun. 29, 2013	Jun. 30, 2012
Net sales	$ 1,144,200,000	[1]	$ 1,004,200,000	[2]	$ 979,000,000	[3]	$ 933,400,000	[4]	$ 967,200,000	[5]	$ 919,800,000	[6]	$ 883,000,000	[7]	$ 769,800,000	[8]	$ 4,060,800,000	$ 3,539,800,000	$ 3,173,200,000
Gross profit	415,700,000	[1]	315,000,000	[2]	360,700,000	[3]	356,300,000	[4]	356,200,000	[5]	331,400,000	[6]	307,200,000	[7]	285,300,000	[8]	1,447,700,000	1,280,000,000	1,095,600,000
Net income	131,700,000	[1]	48,100,000	[2]	(86,000,000)	[3]	111,400,000	[4]	118,500,000	[5]	111,900,000	[6]	106,000,000	[7]	105,600,000	[8]	205,300,000	441,900,000	401,600,000
Earnings (loss) per share:
Basic earnings per share	$ 0.98	[1],[9]	$ 0.36	[2],[9]	$ (0.87)	[3],[9]	$ 1.18	[4],[9]	$ 1.26	[5]	$ 1.19	[6],[9]	$ 1.13	[7],[9]	$ 1.13	[8]	$ 1.78	$ 4.71	$ 4.31
Diluted earnings per share	$ 0.98	[1],[9]	$ 0.36	[2],[9]	$ (0.87)	[3],[9]	$ 1.18	[4],[9]	$ 1.25	[5]	$ 1.18	[6],[9]	$ 1.12	[7],[9]	$ 1.12	[8]	$ 1.77	$ 4.68	$ 4.27
Weighted average shares outstanding
Basic	133.8	[1]	133.7	[2]	98.7	[3]	94.2	[4]	94.0	[5]	94.0	[6]	93.9	[7]	93.6	[8]	115.1	93.9	93.2
Diluted	134.3	[1]	134.3	[2]	98.7	[3]	94.7	[4]	94.6	[5]	94.5	[6]	94.5	[7]	94.3	[8]	115.6	94.5	94.1
Selected Quarterly Financial Information [Abstract]
Business Acquisition, Transaction Costs			3,200,000		103,200,000		12,000,000
Litigation Settlement, Expense							2,500,000
Acquisition Costs, Period Cost							1,900,000
Restructuring charges	10,500,000		19,500,000		14,900,000												47,000,000	2,900,000	8,800,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability			5,800,000		4,900,000
Total loss on extinguishment of debt					165,800,000												(165,800,000)	0	0
Write-off of in-process research and development					6,000,000												6,000,000	9,000,000	0
Loss on sales of investments											1,600,000						12,700,000	4,700,000	0
Texas Medicaid [Member]
Selected Quarterly Financial Information [Abstract]
Loss Contingency Accrual	15,000,000																15,000,000
Rosemont Pharmaceuticals Ltd. [Domain]
Selected Quarterly Financial Information [Abstract]
Pre-tax charge to cost of sales for step-in in value of inventory									1,200,000		1,900,000
Rosemont Pharmaceuticals Ltd. [Domain] | Distribution And License Agreements [Member]
Selected Quarterly Financial Information [Abstract]
Pre-tax charge to cost of sales for step-in in value of inventory																		3,200,000
Velcera, Inc. [Domain]
Selected Quarterly Financial Information [Abstract]
Acquisition Costs, Period Cost									5,600,000
Restructuring charges																	1,400,000	2,900,000
Rosemont and Velcera [Member]
Selected Quarterly Financial Information [Abstract]
Acquisition Costs, Period Cost											3,100,000
Sergeant's Pet Care Products, Inc. [Domain]
Selected Quarterly Financial Information [Abstract]
Acquisition Costs, Period Cost							1,900,000
Sergeant's Pet Care Products, Inc. [Domain] | Distribution And License Agreements [Member]
Selected Quarterly Financial Information [Abstract]
Pre-tax charge to cost of sales for step-in in value of inventory													7,700,000
Cobrek Pharmaceuticals, Inc. [Domain]
Selected Quarterly Financial Information [Abstract]
Severance Costs													1,500,000
Loss on sales of investments													$ 3,000,000

[1] Includes restructuring charges totaling $10.5 million and a loss contingency of $15.0 million related to Texas Medicaid.

[2] Includes restructuring charges totaling $19.5 million, write-up of contingent consideration of $5.8 million related to Fera, and $3.2 million of Elan transaction costs.

[3] Includes loss on extinguishment of debt of $165.8 million, Elan transaction costs of $103.2 million, restructuring charges totaling $14.9 million, write-off of contingent consideration of $4.9 million related to Fera, and write-off of IPR&D of $6.0 million related to Paddock and Rosemont.

[4] Includes Elan transaction costs of $12.0 million, litigation settlement of $2.5 million, and acquisition costs of $1.9 million.

[5] Includes a pre-tax charge to cost of sales of $1.2 million associated with the step-up in value of inventory related to the Rosemont acquisition, $5.6 million of restructuring and other integration-related costs associated with the Velcera acquisition and a $9.0 million impairment charge related to the write-off of IPR&D.

[6] Includes a pre-tax charge to cost of sales of $1.9 million associated with the step-up in value of inventory related to the Rosemont acquisition, approximately $3.1 million of acquisition costs associated with the Rosemont and Velcera acquisitions and a $1.6 million loss related to the sale of the Company's investment securities.

[7] Includes a pre-tax charge to cost of sales of $7.7 million associated with the step-up in value of inventory related to the Sergeant's acquisition, $1.5 million of severance costs associated with the Cobrek acquisition and a $3.0 million loss on the sale of investment related to Cobrek.

[8] Includes a pre-tax charge of approximately $1.9 million of acquisition costs associated with the Sergeant's acquisition.

[9] The sum of quarterly financial data may vary from the annual data due to rounding. The sum of individual per share amounts may not equal due to rounding.